Bristol Myers Squibb checks 'yes' on another Prothena neurodegenerative therapy
引进/卖出临床2期临床3期临床申请
Preview
来源: FierceBiotech
Prothena’s investigational new drug application for PRX019 was cleared by the FDA in December 2023. Now, Bristol Myers Squibb is paying out $80 million for exclusive global rights.
Bristol Myers Squibb is again dipping into the well of therapies being developed by Prothena, this time for an exclusive license to a neurodegenerative candidate that is about to slide into human testing.
Prothena’s investigational new drug (IND) application for PRX019 was cleared by the FDA in December 2023, and, now, BMS is paying out $80 million for exclusive global rights. The therapy is aimed at an undisclosed target, and a trial is expected to get underway by the end of this year, according to a Tuesday evening press release.
This is the second clinical program to come out of the Prothena-BMS collaboration after the Big Pharma paid out $55 million for a worldwide license to clinical-phase Alzheimer’s disease candidate PRX005 in July 2023. BMS previously paid $80 million to ProthenaProthena for an initial opt-in on U.S. rights to PRX005 in 2021.
The companies also share a preclinical amyotrophic lateral sclerosis treatment called TDP-43.
Prothena has additional deals with Novo Nordisk to work on a phase 2 ATTR amyloidosis candidate and Roche, where the companies are developing prasinezumab for Parkinson’s disease, also in phase 2.
Furthest along in the pipeline is birtamimab, which Prothena is developing alone for AL amyloidosis in phase 3.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。